Phase I
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 16, 2021.
It was a busy week for clinical trial announcements and news. Here’s a look.
With billions invested in R&D over the past year to find vaccines and therapies for the novel coronavirus, a few select life sciences companies and academic institutions are working on the hypothesis that intranasal vaccines and therapies could be key to stopping COVID-19 in its tracks, and provide greater protection against transmission of COVID-19.
The company’s head of drug development, Samit Hirawat, told analysts in a conference call last week that the decision was about working with the best drugs, particularly in a crowded field like BCMA.
Switzerland-based AC Immune SA announced positive interim results from its ongoing Phase Ib/IIa clinical trial of ACI-35.030 for Alzheimer’s disease.
While the space is just beginning to emerge, therapies for long-haul COVID-19 patients are still very much an unmet need.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 9, 2021.
Foster City-based Gilead Sciences says its inhaled version of remdesivir, which has been increasingly used in research and practice to combat COVID-19 in hospitalized patients, won’t be available any time soon as it needs more testing in clinical research.
It was a busy week for clinical trial updates. Here’s a look.
Amgen released its fourth-quarter and full-year 2020 results today and although there was good news financially, there was also news of five cancer programs that have either been halted or abandoned.
PRESS RELEASES